<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37961575</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Reduced Monocyte Proportions and Responsiveness in Convalescent COVID-19 Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.10.25.563806</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.10.25.563806</ELocationID><Abstract><AbstractText>The clinical manifestations of acute severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and COVID-19 suggest a dysregulation of the host immune response that leads to inflammation, thrombosis, and organ dysfunction. It is less clear whether these dysregulated processes persist during the convalescent phase of disease or during long COVID. We investigated the effects of SARS-CoV-2 infection on the proportions of classical, intermediate, and non-classical monocytes, their activation status, and their functional properties in convalescent COVID-19 patients and uninfected control subjects. We found that the percentage of total monocytes was decreased in convalescent COVID-19 patients compared to uninfected controls. This was due to decreased intermediate and non-classical monocytes. Classical monocytes from convalescent COVID-19 patients demonstrated a decrease in activation markers, such as CD56, in response to stimulation with bacterial lipopolysaccharide (LPS). In addition, classical monocytes from convalescent COVID-19 patients showed decreased expression of CD142 (tissue factor), which can initiate the extrinsic coagulation cascade, in response to LPS stimulation. Finally, we found that monocytes from convalescent COVID-19 patients produced less TNF-&#x3b1; and IL-6 in response to LPS stimulation, than those from uninfected controls. In conclusion, SARS-CoV-2 infection exhibits a clear effect on the relative proportions of monocyte subsets, the activation status of classical monocytes, and proinflammatory cytokine production that persists during the convalescent phase of disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ravkov</LastName><ForeName>Eugene V</ForeName><Initials>EV</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Elizabeth S C P</ForeName><Initials>ESCP</Initials></Author><Author ValidYN="Y"><LastName>Elgort</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Adam P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Planelles</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Spivak</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Delgado</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hanley</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-6253-6850</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Front Immunol. 2024 Jan 04;14:1329026. doi: 10.3389/fimmu.2023.1329026</RefSource><PMID Version="1">38250080</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37961575</ArticleId><ArticleId IdType="pmc">PMC10634809</ArticleId><ArticleId IdType="doi">10.1101/2023.10.25.563806</ArticleId><ArticleId IdType="pii">2023.10.25.563806</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>